Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer

Lucy J. Schmidt, Donald J. Tindall

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Steroid 5 alpha-reductase inhibitors (5ARIs) have been approved for use clinically in treatment of benign prostate hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) and have also been evaluated in clinical trials for prevention and treatment of prostate cancer. There are currently two steroidal inhibitors in use, finasteride and dutasteride, both with distinct pharmacokinetic properties. This review will examine the evidence presented by various studies supporting the use of these steroidal inhibitors in the prevention and treatment of prostate disease. Article from the Special issue on Targeted Inhibitors.

Original languageEnglish (US)
Pages (from-to)32-38
Number of pages7
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume125
Issue number1-2
DOIs
StatePublished - May 2011

Fingerprint

5-alpha Reductase Inhibitors
Finasteride
Pharmacokinetics
Hyperplasia
Prostate
Prostatic Neoplasms
Oxidoreductases
Steroids
Lower Urinary Tract Symptoms
Clinical Trials
Dutasteride

Keywords

  • 5 Alpha-reductase inhibition
  • Chemoprevention
  • Prostate disease

ASJC Scopus subject areas

  • Molecular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Cell Biology
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer. / Schmidt, Lucy J.; Tindall, Donald J.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 125, No. 1-2, 05.2011, p. 32-38.

Research output: Contribution to journalArticle

Schmidt, Lucy J. ; Tindall, Donald J. / Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer. In: Journal of Steroid Biochemistry and Molecular Biology. 2011 ; Vol. 125, No. 1-2. pp. 32-38.
@article{e325f9f155744e6f94a1fc1ae331d26c,
title = "Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer",
abstract = "Steroid 5 alpha-reductase inhibitors (5ARIs) have been approved for use clinically in treatment of benign prostate hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) and have also been evaluated in clinical trials for prevention and treatment of prostate cancer. There are currently two steroidal inhibitors in use, finasteride and dutasteride, both with distinct pharmacokinetic properties. This review will examine the evidence presented by various studies supporting the use of these steroidal inhibitors in the prevention and treatment of prostate disease. Article from the Special issue on Targeted Inhibitors.",
keywords = "5 Alpha-reductase inhibition, Chemoprevention, Prostate disease",
author = "Schmidt, {Lucy J.} and Tindall, {Donald J.}",
year = "2011",
month = "5",
doi = "10.1016/j.jsbmb.2010.09.003",
language = "English (US)",
volume = "125",
pages = "32--38",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "1-2",

}

TY - JOUR

T1 - Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer

AU - Schmidt, Lucy J.

AU - Tindall, Donald J.

PY - 2011/5

Y1 - 2011/5

N2 - Steroid 5 alpha-reductase inhibitors (5ARIs) have been approved for use clinically in treatment of benign prostate hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) and have also been evaluated in clinical trials for prevention and treatment of prostate cancer. There are currently two steroidal inhibitors in use, finasteride and dutasteride, both with distinct pharmacokinetic properties. This review will examine the evidence presented by various studies supporting the use of these steroidal inhibitors in the prevention and treatment of prostate disease. Article from the Special issue on Targeted Inhibitors.

AB - Steroid 5 alpha-reductase inhibitors (5ARIs) have been approved for use clinically in treatment of benign prostate hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) and have also been evaluated in clinical trials for prevention and treatment of prostate cancer. There are currently two steroidal inhibitors in use, finasteride and dutasteride, both with distinct pharmacokinetic properties. This review will examine the evidence presented by various studies supporting the use of these steroidal inhibitors in the prevention and treatment of prostate disease. Article from the Special issue on Targeted Inhibitors.

KW - 5 Alpha-reductase inhibition

KW - Chemoprevention

KW - Prostate disease

UR - http://www.scopus.com/inward/record.url?scp=79957696618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957696618&partnerID=8YFLogxK

U2 - 10.1016/j.jsbmb.2010.09.003

DO - 10.1016/j.jsbmb.2010.09.003

M3 - Article

C2 - 20883781

AN - SCOPUS:79957696618

VL - 125

SP - 32

EP - 38

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 1-2

ER -